Skip to main content
SpringerLink
Log in

Direct-to-sequencing vs immunohistochemistry protocol for Lynch Syndrome?

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Gudgeon JM, et al. Model-Based Re-Examination of the Effectiveness of Tumor/Immunohistochemistry and Direct-to-Sequencing Protocols for Lynch Syndrome Case Finding in Endometrial Cancer. JCO Oncology Practice : OP2000988, 22 Apr 2021

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Direct-to-sequencing vs immunohistochemistry protocol for Lynch Syndrome?. PharmacoEcon Outcomes News 878, 9 (2021). https://doi.org/10.1007/s40274-021-7695-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-021-7695-y

Search

Navigation